Saturday, 31 October 2026European Markets

BEVER HOLDING Stock Over 18% Up In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of BEVER HOLDING (AEX-Index: BEVER.AS) rose by a staggering 18.12% in 5 sessions from €2.76 to €3.26 at 05:09 EST on Wednesday, after two consecutive sessions in a row of losses. AEX-Index is sliding 0.97% to €756.67, after two consecutive sessions in a row of losses.

BEVER HOLDING's last close was €3.26, 24.19% under its 52-week high of €4.30.

About BEVER HOLDING

Bever Holding NV operates as a real estate company in the Netherlands and Belgium. It develops apartments, commercial spaces, and hotels. The company also invests in, acquires, and leases real estate properties. Bever Holding NV was incorporated in 1975 and is based in Wassenaar, the Netherlands.

Earnings Per Share

As for profitability, BEVER HOLDING has a trailing twelve months EPS of €-1.12.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -47.79%.

Moving Average

BEVER HOLDING's value is under its 50-day moving average of €3.58 and way under its 200-day moving average of €3.68.

Yearly Top and Bottom Value

BEVER HOLDING's stock is valued at €3.26 at 05:09 EST, way below its 52-week high of €4.30 and way above its 52-week low of €2.76.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.7%, now sitting on 1.05M for the twelve trailing months.

Volume

Today's last reported volume for BEVER HOLDING is 257 which is 115.96% above its average volume of 119.

More news about BEVER HOLDING (BEVER.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com